The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
hERG channel trafficking: novel targets in drug-induced long QT syndrome
Abstract
The cardiac potassium channel hERG (human ether-a-go-go-related gene) encodes the α-subunit of the rapid delayed rectifier current IKr in the heart, which contributes to terminal repolarization in human cardiomyocytes. Direct block of hERG/IKr channels by a large number of therapeutic compounds produces acLQTS [acquired LQTS (long QT syndrome)] characterized by drug-induced QT prolongation and torsades de pointes arrhythmias. The cardiotoxicity associated with unintended hERG block has prompted pharmaceutical companies to screen developmental compounds for hERG blockade and made hERG a major target in drug safety programmes. More recently, a novel form of acLQTS has been discovered that may go undetected in most conventional safety assays. Several therapeutic compounds have been identified that reduce hERG/IKr currents not by direct block but by inhibition of hERG/IKr trafficking to the cell surface. Important examples are antineoplastic Hsp90 (heat-shock protein 90) inhibitors such as (i) geldanamycin, (ii) the leukaemia drug arsenic trioxide, (iii) the antiprotozoical pentamidine, (iv) probucol, a cholesterol-lowering drug, and (v) fluoxetine, a widely used antidepressant. Increased awareness of drug-induced hERG trafficking defects will help to further reduce the potentially lethal adverse cardiac events associated with acLQTS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ich function is dependent upon their appropriate location and abundance within the cells, which is regulated by a delicate equilibrium between endocytic, secretory, and degradative pathways [79,80,81].”
From Insights of Endocytosis Signaling in Health and Disease (2023) · cites this paper as [81]
Citations
Cites
Sanguinetti, M. C., Jiang, C., Curran, M. E., & Keating, M. T. (1995) · Cell · doi:10.1016/0092-8674(95)90340-2 · Cited by 2,423
hERG potassium channels and cardiac arrhythmia
Sanguinetti, M. C., & Tristani-Firouzi, M. (2006) · Nature · doi:10.1038/nature04710 · Cited by 1,572
Molecular and Cellular Mechanisms of Cardiac Arrhythmias
Keating, M. T., & Sanguinetti, M. C. (2001) · Cell · doi:10.1016/s0092-8674(01)00243-4 · Cited by 1,001
Hieronymus, H., Lamb, J., Ross, K. N., Peng, X. P., Clement, C., Rodina, A., Nieto, M., Du, J., Stegmaier, K., Raj, S. M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.005 · Cited by 624
Heat shock protein 90 as a molecular target for cancer therapeutics
Isaacs, J. S., Xu, W., & Neckers, L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00029-1 · Cited by 577
The impact of drug-induced QT interval prolongation on drug discovery and development
Fermini, B., & Fossa, A. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1108 · Cited by 492
Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism
Anderson, C. L., Delisle, B. P., Anson, B. D., Kilby, J. A., Will, M. L., Tester, D. J., Gong, Q., Zhou, Z., Ackerman, M. J., & January, C. T. (2006) · Circulation · doi:10.1161/circulationaha.105.570200 · Cited by 408
Drug‐Induced Torsades de Pointes and Implications for Drug Development
FENICHEL, R. R., MALIK, M., ANTZELEVITCH, C., SANGUINETTI, M., RODEN, D. M., PRIORI, S. G., RUSKIN, J. N., LIPICKY, R. J., CANTILENA, L. R., & Independent Academic Task Force (2004) · Journal of Cardiovascular Electrophysiology · doi:10.1046/j.1540-8167.2004.03534.x · Cited by 346
Role of the Cytosolic Chaperones Hsp70 and Hsp90 in Maturation of the Cardiac Potassium Channel hERG
Ficker, E., Dennis, A. T., Wang, L., & Brown, A. M. (2003) · Circulation Research · doi:10.1161/01.res.0000079028.31393.15 · Cited by 323
Self-citationPredicting drug–hERG channel interactions that cause acquired long QT syndrome
Sanguinetti, M. C., & Mitcheson, J. S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.01.003 · Cited by 300
Cited by
Voltage-gated potassium channels as therapeutic targets
Wulff, H., Castle, N. A., & Pardo, L. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2983 · Cited by 799
The hERG potassium channel and hERG screening for drug-induced torsades de pointes
Hancox, J. C., McPate, M. J., El Harchi, A., & Zhang, Y. H. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.05.009 · Cited by 299
Insights of Endocytosis Signaling in Health and Disease
Pathak, C., Vaidya, F. U., Waghela, B. N., Jaiswara, P. K., Gupta, V. K., Kumar, A., Rajendran, B. K., & Ranjan, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032971 · Cited by 59
Metadata
- Authors
- Dennis, A., Wang, L., Wan, X., & Ficker, E.
- Affiliations
- MetroHealth (US)
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2007-10-25
- Volume
- 35
- Issue
- 5
- Pages
- 1060-1063
- ISSN
- 0300-5127 (ISSN-L)
- 1470-8752
- OpenAlex
- W2063315937
- Cited by
- 134
- References
- 28
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 7 · 2022: 2 · 2021: 4 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 8 · 2016: 7 · 2015: 4 · 2014: 14 · 2013: 14 · 2012: 8
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemical Society Transactions (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Keywords
- hERG, drug-induced long QT syndrome, acquired long QT syndrome, channel trafficking, cardiac potassium channels, IKr current, torsades de pointes, drug-induced cardiotoxicity, Hsp90 inhibitors, geldanamycin, arsenic trioxide, pentamidine, probucol, fluoxetine, drug safety testing
- MeSH terms
- ERG1 Potassium Channel, Humans, Long QT Syndrome, HSP90 Heat-Shock Proteins, Protein Transport, Ether-A-Go-Go Potassium Channels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: hERG channel trafficking: novel targets in drug-induced long QT syndrome. https://app.cochat.ai/papers/10.1042/bst0351060
- The paper
- Dennis, A., Wang, L., Wan, X., & Ficker, E. (2007). hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochemical Society Transactions. https://doi.org/10.1042/bst0351060
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.